Google Prepares for 2-for-1 Split; Teva Gets Okay from U.S. Supreme Court to Appeal

Investment Opinion

Share Tweet

Google Prepares for 2-for-1 Split; Teva Gets Okay from U.S. Supreme Court to Appeal

Teva Pharmaceutical Industries Limited (NYSE: TEVA) – For an in-depth report on Teva Pharmaceutical Industries Limited follow:

TEVA shares closed up 6.86% on Monday with about 13.6 million shares traded. The stock was one of the most active stocks on the NYSE and hit a new yearly high of $52.94 during intra-day trading. The U.S. Supreme Court today decided that it will hear an appeal filed by the company that develops, produces and markets generic drugs in all treatment categories. TEVA is in a patent fight over its bestselling multiple sclerosis drug Copaxone.

Micron Technology Inc. (NASDAQ: MU) - For an in-depth report on Micron Technology Inc. follow:

Shares of Micron Technology closed up 7.99% on about 39.6 million shares traded, making it one of the biggest gainers on the NASDAQ. It was actually the top gainer on the S&P 500. The company will announce its Q2 2014 results on April 3. Micron saw a 120% year-over-year growth in its Q1 2014 earnings.

Google Inc. (NASDAQ: GOOG) - For an in-depth report on Google Inc. follow:

Shares of GOOG saw a modest price drop on Monday as it was revealed that Google would finally see a 2-for-1 split on April 3rd. RBC analyst Mark Mahaney, in a research note, upped his target to a split-adjusted 710 from 700. As of March 27, holders of Class A and Class B shares are scheduled on Tuesday after the market close to receive one new Class C share for each Google share they own.

Federal National Mortgage Association (OTCBB: FNMA) – For an in-depth report on Federal National Mortgage Association follow:

Shares of FNMA closed up 9.24% on about 29.7 million shares traded. The gain came after it was announced that Bill Ackman's firm, Pershing Square Capital Management, is increasing its stake in Fannie Mae and Freddie Mac to over 11% in each from a combined 9.8% in both firms, according to a CNBC report. 


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.